ClinicalTrials.gg
RecruitingNCT04284397Updated Jan 27, 2026

Identification of Critical Thermal Environments for Aged Adults

An Early Phase 1 interventional study of Low dose ASA and Control in Aging, sponsored by Penn State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Penn State University · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Heat Stress Disorders with a site in United States — 11 open to participants now, 13 under way, none of them phase 3. Heat Stress Disorders · United States.

Planned enrollment
2nd of 27
190 · median 24
Started
2020
the only one that year
Phase 1
Only one
of the 33
Primary completion
2027-02
later than 6 of 12 live
Registered
8th of 33
by date
Lead sponsor
4 of 33
Penn State University

Among the 33 studies in Heat Stress Disorders with a site in United States, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 1, reaches primary completion later than 6 of the 12 other live ones, and was the 8th registered.

Heat Stress Disorders

118 studies on the registry are indexed under Heat Stress Disorders; 42 are open to participants now.

Browse Heat Stress Disorders studies →

Open to participants now

11 of the 33 studies in Heat Stress Disorders with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Heat Stress Disorders studies recruiting now, 8 (27%) set no upper age limit and 18 (60%) stop at 75 or younger; 6 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Heat Stress Disorders with a site in United States, or all of them as a file.
02

Study summary

This study evaluates critical environmental limits (temperature and humidity) above which older adults are unable to effectively thermoregulate. Participants will exercise in a series of different environmental conditions to identify combinations of temperature and humidity above which age-related physiological changes cause uncompensable heat stress, resulting in increased risk of heat illness.

Read the detailed description

The earth's climate is warming well above historical averages, and there is an increased frequency, duration, and severity of heat waves. At the same time, the world's population is rapidly aging. Aging is associated with reductions in thermoregulatory capacity due to reductions in sweating and skin blood flow. For this reason, people ≥65 years exhibit exponentially larger increases in morbidity and mortality during heat waves than younger individuals, with the large majority of excess deaths during heat waves occurring in the elderly.

Compounding the physiological effects of primary aging, co-morbidities and common classes of drugs taken by older adults can further compromise their thermoregulatory function. One such class of medications is cyclooxygenase inhibitors, including aspirin (ASA) and other platelet inhibitors. Provocative data published by our lab indicate that platelet inhibitors including ASA increase the rate of heat storage during passive heat stress by \~25%. Following current clinical guidelines, nearly 40% of US adults over the age of 50 engage in an aspirin therapy regiment for the primary or secondary prevention of cardiovascular disease.

Although there is compelling evidence that aging is associated with decreased heat dissipation and elevated risk of heat illness in hot ambient conditions, the significant question remains: In what specific environments does this age disparity begin to occur? The goal of the current study is to identify and model ambient conditions that are unsafe for older adults. A second aim of the study is to determine the effects of the commonly used platelet inhibitor, acetylsalicylic acid (ASA), on age-specific critical environmental limits.

03

Conditions studied

  • Aging

Browse trials for

Keywords

  • Aging
  • Thermoregulation
  • Heat stress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 and older (those 40+ years of age must be cleared by collaborating physician)
  • All premenopausal women will be eumenorrheic (by survey)
  • Asymptomatic and no signs/symptoms of disease according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription

Exclusion criteria

Exclusion Criteria:

  • Medications that affect thermoregulatory or cardiovascular responses to exercise
  • Any to low intensity physical activity on the Physical Activity Readiness Questionnaire
  • Any mobility restrictions that interfere with low intensity physical activity
  • Pregnant or planning to become pregnant in the next 12 months
  • Prior diagnosis of cancer, cardiovascular disease, diabetes, or metabolic syndrome
  • Illegal/recreational drug use
  • History of Chron's disease, diverticulitis, or similar gastrointestinal disease
  • Abnormal resting or exercise (ECG)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Critical Environmental Limits

    Subjects will perform exercise at \~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.

    Other: Control

  • Experimental
    Aspirin Supplementation

    After a minimum of 7 days of daily, low-dose aspirin ingestion, older subjects will repeat critical environmental limits trials. As before, subjects will perform exercise at \~200-300W with ambient temperature or humidity increasing every 5 min throughout the trial until core temperature begins to rise.

    Drug: Low dose ASA

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.

    Also known as: Low-dose aspirin

  • OtherControl

    All participants will be tested with no treatment.

06

What researchers measure

Primary outcomes

  1. Temperature and humidity limits for maintaining stable core temperature

    Core temperature will be measured throughout exercise. The point at which heat stress becomes uncompensable will be determined for each environmental and exercise condition by assessing the combination of temperature and humidity at which core temperature begins to rise.

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. Core temperature

    Core temperature will be monitored throughout each experimental visit

    Time frame: Continuous throughout visit until completion of exercise; an average of 2 hours.

  2. Sweat rate

    Sweat rate will be determined by measuring nude body mass before and after each experimental visit

    Time frame: Immediately before and immediately after exercise.

  3. Skin temperature

    Skin temperature will be monitored throughout each experimental visit

    Time frame: Continuous throughout visit until completion of exercise; an average of 2 hours.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Feb 2027, 73 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Feb 25, 2020
StartActual
Dec 30, 2020
Primary completionEst.
Feb 27, 2027
CompletionEst.
Feb 27, 2027
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04284397
Responsible party
W. Larry Kenney (Professor, Penn State University) — Principal investigator
First posted
Feb 25, 2020
Start date
Dec 30, 2020
Primary completion
Feb 27, 2027 (estimated)
Completion
Feb 27, 2027 (estimated)
Last update
Jan 27, 2026

Study contacts

Lacy M Alexander, Ph.D.
Contact
lma191@psu.edu
8148671781
W. Larry Kenney, Ph.D.
principal investigator · The Pennsylvania State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion